Apellis shares are trading lower after the company announced the CHMP has adopted a negative opinion on the marketing authorization application of intravitreal pegcetacoplan for the treatment of geographic atrophy.
Portfolio Pulse from Benzinga Newsdesk
Apellis shares are trading lower after the company announced that the CHMP has adopted a negative opinion on the marketing authorization application of intravitreal pegcetacoplan for the treatment of geographic atrophy.
June 28, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis shares are trading lower due to a negative opinion from the CHMP on the marketing authorization application of intravitreal pegcetacoplan for geographic atrophy treatment.
The negative opinion from the CHMP significantly impacts Apellis' prospects for intravitreal pegcetacoplan, a key product for the treatment of geographic atrophy. This regulatory setback is likely to weigh heavily on investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100